{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:27:17Z","timestamp":1707524837925},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,17]]},"DOI":"10.7759\/cureus.32646","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T19:12:54Z","timestamp":1671304374000},"source":"Crossref","is-referenced-by-count":0,"title":["Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis"],"prefix":"10.7759","author":[{"given":"Liri","family":"Cuko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonila","family":"Bele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Babameto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irgen","family":"Tafaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlinda","family":"Hysenj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Shagla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agron","family":"Dogjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017, 2:161-76. 10.1016\/S2468-1253(16)30181-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30045-6","article-title":"Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study","volume":"2","author":"European Union HCV Collaborators","year":"2017","unstructured":"European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017, 2:325-36. 10.1016\/S2468-1253(17)30045-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14537","article-title":"Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts","volume":"40","author":"Mangia A","year":"2020","unstructured":"Mangia A, Milligan S, Khalili M, et al.. Global real-world evidence of sofosbuvir\/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver Int. 2020, 40:1841-52. 10.1111\/liv.14537","journal-title":"Liver Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz E","year":"2020","unstructured":"Lawitz E, Flisiak R, Abunimeh M, et al.. Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int. 2020, 40:1032-41. 10.1111\/liv.14320","journal-title":"Liver Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/1574887114666190306154650","article-title":"Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection","volume":"14","author":"Scotto R","year":"2019","unstructured":"Scotto R, Buonomo AR, Moriello NS, et al.. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection. Rev Recent Clin Trials. 2019, 14:173-82. 10.2174\/1574887114666190306154650","journal-title":"Rev Recent Clin Trials"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14301","article-title":"Cost-effectiveness of generic pan-genotypic sofosbuvir\/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment","volume":"33","author":"Goel A","year":"2018","unstructured":"Goel A, Chen Q, Chhatwal J, Aggarwal R. Cost-effectiveness of generic pan-genotypic sofosbuvir\/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. J Gastroenterol Hepatol. 2018, 33:2029-36. 10.1111\/jgh.14301","journal-title":"J Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster GR","year":"2016","unstructured":"Foster GR, Irving WL, Cheung MC, et al.. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016, 64:1224-31. 10.1016\/j.jhep.2016.01.029","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","year":"2018","unstructured":"EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018, 69.461-511. 10.1016\/j.jhep.2018.03.026","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57 Suppl 2","author":"Martin NK","year":"2013","unstructured":"Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013, 57 Suppl 2:S39-45. 10.1093\/cid\/cit296","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model","volume":"393","author":"Heffernan A","year":"2019","unstructured":"Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019, 393:1319-29. 10.1016\/S0140-6736(18)32277-3","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32750-8","article-title":"How feasible is the global elimination of HCV infection?","volume":"393","author":"Wiktor S","year":"2019","unstructured":"Wiktor S. How feasible is the global elimination of HCV infection?. Lancet. 2019, 393:1265-7. 10.1016\/S0140-6736(18)32750-8","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1812959","article-title":"Brazil's fight against hepatitis C - universalism, local production, and patents","volume":"380","author":"da Fonseca EM","year":"2019","unstructured":"da Fonseca EM, Shadlen K, Bastos FI. Brazil's fight against hepatitis C - universalism, local production, and patents. N Engl J Med. 2019, 380:605-7. 10.1056\/NEJMp1812959","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/125165-direct-acting-antiviral-treatment-in-albanian-patients-with-chronic-hepatitis-c-and-advanced-liver-fibrosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:37Z","timestamp":1707507997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/125165-direct-acting-antiviral-treatment-in-albanian-patients-with-chronic-hepatitis-c-and-advanced-liver-fibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.32646","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,17]]}}}